DC1: Design and discovery of novel GrnzB ligands and evaluation as diagnostics tools in CAR T cell therapy assessment

  • Host organisation: University of Antwerp, Belgium
  • PhD-enrolment: University of Antwerp, Belgium
  • Duration: 36 months
  • Expected start date: January 2023
  • Academic secondment: University of Bern, Switzerland (2 months)
  • Industrial secondment: CellCarta, Belgium (6 months)

DC2: Novel probes for imaging of tumor-associated proteases via Positron Emission Tomography (PET) and fluorescence microscopy

  • Host organisation: University of Antwerp, Belgium
  • PhD-enrolment: University of Antwerp, Belgium
  • Duration: 36 months
  • Expected start date: January 2023
  • Academic secondment: University of Mainz, Germany (2 months)
  • Industrial secondment: Fox Biosystems, Belgium (5 months)

DC3: Innovative Target Modulators (TMs) for simultaneous delivery of CAR T cell therapy, radio- and chemotherapy to tumors

  • Host organisation: University of Copenhagen, Denmark
  • PhD-enrolment: University of Copenhagen, Denmark
  • Duration: 36 months
  • Expected start date: January 2023
  • Academic secondment: HZDR, Germany (4 months)
  • Industrial secondment: CROmed, Hungary (5 months)

DC4:  Innovative Target Modulators for FAP-targeting UniCAR T therapy

  • Host organisation: Helmholtz Zentrum Dresden Rossendorf (HZDR), Germany 
  • PhD-enrolment: TU-Dresden, Germany
  • Duration: 36 months
  • Expected start date: January 2023
  • Academic secondment: University of Copenhagen, Denmark (6 months)
  • Industrial secondment: CROmed, Hungary (5 months)

DC5: Design and discovery of novel cathepsin S ligands and their evaluation as PET and fluorescent probes for oncology diagnosis 

  • Host organisation: University of Mainz, Germany
  • PhD enrolment: University of Mainz, Germany
  • Duration: 36 months
  • Expected start date: January 2023
  • Academic secondment: CSIC-CNB, Spain (4 months)
  • Industrial secondment: SCV (Spezial-Chemikalien-Vertriebs-GmbH), Germany (3 months)

DC6: Characterization of the p38 MAPK pathway in the expression of TME proteases

  • Host organisation: Agencia Estatal Consejo Superior de Investigaciones Científicas (CSIC), Spain
  • PhD-enrolment: Universidad Autónoma de Madrid (UAM), Spain ​
  • Duration: 36 months
  • Expected start date: January 2023
  • Academic secondment: University of Antwerp, Belgium (5 months)
  • Industrial secondment: Cellply, Italy (3 months)

DC7: In vivo investigation of FAP-targeting UniCAR T cell therapies combined with radio- and chemotherapy

  • Host organisation: CROmed, Hungary
  • PhD-enrolment: Semmelweis University, Hungary
  • Duration: 36 months
  • Expected start date: January 2023
  • Academic secondment: Inselspital, Switzerland (3 months)
  • Industrial secondment: none, since CROmed offers the industrial training environment 

DC8: Novel probes for imaging of tumor-associated cathepsins via Positron Emission Tomography (PET) and fluorescence microscopy

  • Host organisation: University of Lisbon, Portugal
  • PhD-enrolment: University of Lisbon, Portugal
  • Duration: 36 months
  • Expected start date: January 2023
  • Academic secondment: University of Antwerp, Belgium (4 months)
  • Industrial secondment: CROmed, Hungary (4 months)

DC9: Microfluidics-based, multilevel cellular phenotyping of lymphoma cells and CAR T cells and in vivo validation

  • Host organisation: CellPly, Italy
  • PhD-enrolment: University of Bologna, Italy
  • Duration: 36 months
  • Expected start date: January 2023
  • Academic secondment: HZDR, Germany (5 months)
  • Industrial secondment: none, since CellPly offers the industrial training environment 

DC10:  Innovative in vitro and in vivo models for TME protease research

  • Host organisation: University of Bern, Switzerland
  • PhD-enrolment: University of Bern, Switzerland
  • Duration: 36 months
  • Expected start date: January 2023
  • Academic secondment: CSIC-CNB, Spain (5 months)
  • Industrial secondment: CellPly, Italy (5 months)